In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023.  According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery.   Check out the Evaluate team’s thoughts on the […]